Attovia Therapeutics ATTO

Angie You, Ph.D. has served as a member of our board of directors since July 2024. Dr. You has also served as Chief Executive Officer and board member of Architect Therapeutics, LLC, a biotechnology company, since March 2023; as a senior advisor to Frazier Life Sciences, since February 2022; and on the board of directors of Candid Therapeutics, Inc., a private biotechnology company, since October 2024. Dr. You also served as advisor to Casdin Capital, LLC, a life sciences and healthcare investment firm, from April 2022 to May 2023. Prior to that, Dr. You served as Chief Executive Officer of Amunix Pharmaceuticals, Inc. (acquired by Sanofi S.A.), an immuno-oncology company, from December 2018 to January 2022. From September 2014 to December 2018, Dr. You served as Chief Business and Strategy Officer and Head of Commercial at Sierra Oncology, Inc., a biotechnology company. Dr. You has served as a member of the board of directors of the following publicly traded companies: ORIC Pharmaceuticals, Inc., a biopharmaceutical company, since November 2021; and RayzeBio, Inc. (acquired by BMS), a biotechnology company, from April 2022 to July 2024. Dr. You has an A.B. in Chemistry from Harvard College and a Ph.D. in Biochemistry from Harvard University.

Mitchell Gold, M.D. has served as a member of our board of directors since July 2024. Dr. Gold has been a venture partner at Frazier Life Sciences since January 2025 and has also served as a managing partner of Alpine BioVentures, GP, LLC, a healthcare investment firm, since September 2013. From January 2015 to July 2024, Dr. Gold served as Chairman, Chief Executive Officer, and founder of Alpine Immune Sciences, Inc. (acquired by Vertex Pharmaceuticals Incorporated), a biotechnology company. From August 2012 to August 2014, Dr. Gold served as chairman and founder of Alpine Biosciences, Inc. (acquired by Cascadian Therapeutics, Inc.). Previously, Dr. Gold was a board member, President and Chief Executive Officer of Dendreon Corporation (acquired by Valeant Pharmaceuticals International, Inc.), a biotechnology company, from May 2001 to February 2013. Dr. Gold has a B.S. in Biology from the University of Wisconsin and an M.D. from Rush University Medical School in Chicago and did his residency in Urology at the University of Washington.

Tao Fu is our founder and has served as our Chief Executive Officer, President and a member of our board of directors since April 2023. He also currently serves as a Venture Partner of Frazier Life Sciences, a life sciences investment firm, since May 2022, and as a board member of Tr1X Inc., a pharmaceutical company, since January 2024. Prior to joining us, Mr. Fu served as President and Chief Operating Officer, and Chief Strategy Officer of Zai Lab Ltd. (Zai Lab), a biopharmaceutical company, from September 2018 to March 2022. From June 2015 to September 2018, Mr. Fu served as Executive Vice President, Chief Commercial and Business Officer of Portola Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Fu served as Vice President and led M&A, Corporate Development and Alliance Management functions at Bristol Myers Squibb Co. (BMS), a biopharmaceutical company, from January 2014 to May 2015. Prior to that, Mr. Fu worked at Johnson & Johnson (J&J), a biopharmaceutical company, from February 2003 to January 2014, with his last position being Vice President, Head of M&A, responsible for J&J's global M&A activities in pharmaceuticals. Mr. Fu also previously held positions with Scios Inc., McKinsey & Company and Becton, Dickinson and Company. Mr. Fu did his undergraduate studies in Biology at Tsinghua University and has a M.S. in Biology from the University of Rochester, and an M.B.A. from Vanderbilt University.

Steven Chan has served as our Chief Financial Officer since October 2024. Prior to joining us, Mr. Chan was the Chief Financial Officer at Connect Biopharma Holdings Limited, a biopharmaceutical company, from November 2021 to September 2024. From April 2019 to November 2021, he served as Chief Financial Officer at Delphon Industries, LLC, a semiconductor manufacturing company. Prior to that, he served as Vice President, Finance & Corporate Controller at Arcus Biosciences, Inc., a biopharmaceutical company, from April 2017 to April 2019 and at MyoKardia, Inc. (acquired by BMS), a biopharmaceutical company, from November 2014 to March 2017. Mr. Chan has also held positions at companies in the biopharmaceutical, financial services, and technology sectors, including Solta Medical Inc., Moody's Analytics, Polycom, Inc. and Logitech, Inc. Mr. Chan received his B.S. in Business Administration from the University of California, Berkeley (UC Berkeley) and is a Certified Public Accountant (inactive).

Petter Veiby is one of our co-founders and has served as our Chief Scientific Officer since June 2023. He also currently serves as a board member of BiVictriX Therapeutics Ltd, a private biotechnology company, since August 2025. Prior to joining us, he was Senior Director at Takeda Oncology, a pharmaceutical company, from November 2022 to June 2023. From April 2022 to November 2022, he was Senior Vice President, Business Development at Immunitas Therapeutics, Inc., a biotechnology company. Prior to that, he was the Head of Alliances and BD Search and Evaluation at Zai Lab from March 2020 to May 2022. From July 1999 to March 2020, he served in various roles with increasing responsibility, including Global Head of Biotherapeutics at Takeda Oncology (originally Millennium Pharmaceuticals). He studied Hematopoietic Stem Cell Biology at the University of Oslo in Norway and completed his postdoctoral studies at the Hipple Cancer Research Center, in Dayton, Ohio, affiliated with Ohio State University.

Zaneta Odrowaz, Ph.D. is one of our co-founders and has served as our Chief Business Officer since April 2023. She has also served as Vice President of Company Creation at Frazier Life Sciences since September 2022. Prior to Frazier Life Sciences, Zaneta served as Senior Director of Corporate Development at Amunix Pharmaceuticals, Inc. (acquired by Sanofi S.A.), a biotechnology company, from April 2020 to June 2022. From October 2018 to March 2020, Dr. Odrowaz was the Chief of Staff to the General Manager at Philips Neuro. Earlier in Dr. Odrowaz's career, she served biopharma and private equity clients as a management consultant at McKinsey & Company. Dr. Odrowaz has a Master's degree in Biotechnology from the Jagiellonian University in Poland, a Ph.D. in Gene Expression from the University of Manchester, U.K., and completed a postdoctoral fellowship in Neuroepigenomics as a Walter V. and Idun Berry fellow at Stanford University.

John W. Smither has served as a member of our board of directors since July 2026. Mr. Smither has served as Chief Financial Officer of MBX Biosciences, Inc., a biopharmaceutical company, since March 2026, and as a senior advisor to Frazier Life Sciences since November 2024. From September 2023 to April 2024, Mr. Smither served as interim Chief Financial Officer of Arcutis Biotherapeutics, Inc., a biopharmaceutical company, where he had previously served as Chief Financial Officer from May 2019 to March 2021. Mr. Smither currently serves as a member of the board of directors of NewAmsterdam Pharma Company N.V., a biopharmaceutical company, since January 2023, where he chairs the audit committee, and of Genelux Corporation, a biopharmaceutical company, since September 2023, where he chairs the compensation committee and is a member of the audit committee. He previously served as a member of the board of directors and chair of the audit committee of eFFECTOR Therapeutics, Inc., a biopharmaceutical company, from March 2018 to September 2023, and of Applied Molecular Transport, Inc., a biopharmaceutical company, from January 2022 to December 2023. Mr. Smither has a B.S. in Business Administration from California State University, Los Angeles.

Colin Walsh, Ph.D. has served as a member of our board of directors since May 2024. Dr. Walsh has also served as Managing Director in the Life Sciences Investing group of Goldman Sachs Group, Inc. since September 2023, and as a board member of Vicebio Limited (acquired by Sanofi S.A.), a private biotechnology company, since September 2024. From April 2019 to October 2023, Dr. Walsh served as a partner at Qiming Venture Partners USA, a healthcare investment firm. Prior to that, Dr. Walsh was a Vice President on the life science investment team at ND Capital LLC, an early-stage venture capital firm, from January 2014 to April 2019. From June 2012 to September 2015, Dr. Walsh held a number of roles at Precision NanoSystems, Inc., a biotechnology company, (acquired by Danaher Corporation). Dr. Walsh has served as a member of the board of directors of the following publicly traded companies: Elevation Oncology, Inc., a biotechnology company, from August 2019 to September 2023; and Korro Bio, Inc., a biotechnology company, from August 2020 to September 2023. Dr. Walsh has a dual B.S. in Chemical Engineering and Biochemistry from the University of Massachusetts, Amherst, a Management of Technology Certificate from the Haas School of Business at UC Berkeley, and a Ph.D. from the UC Berkeley - UCSF Graduate Program in Bioengineering.

Hubert Chen, M.D. has served as our Chief Medical Officer since March 2024. Prior to joining us, Dr. Chen served as Senior Vice President of Clinical Development at Krystal Biotech, Inc., a biotechnology company, from October 2021 to March 2024. From August 2011 to September 2021, Dr. Chen served in various roles at Genentech, Inc., a biotechnology company, most recently as Principal Medical Director starting in March 2020 and as Senior Medical Director from March 2016 to March 2020. Dr. Chen has also previously held several positions at the University of California, San Francisco (UCSF) Medical Center. Dr. Chen has a M.P.H. from Harvard University and received his M.D. from Stanford University. He is board-certified in pulmonary medicine, critical care medicine and internal medicine and received his post-graduate training at the University of California, San Francisco.

Rebecca Luse has served as a member of our board of directors since March 2025. Ms. Luse has also served as Managing Director of Deep Track Capital, L.P., a life sciences investment firm, since January 2021. From October 2019 to January 2021, Ms. Luse served as Principal of New Leaf Venture Partners, a healthcare technology investment firm, and as Vice President from February 2015 to January 2021. Ms. Luse has also served as a member of the board of directors of LB Pharmaceuticals Inc, a publicly traded biopharmaceutical company, since August 2023. From August 2013 to February 2015, Ms. Luse was a research associate on the biotechnology investment team at Jefferies LLC. Prior to that, Ms. Luse was a research associate on the specialty pharmaceuticals investment team at Piper Jaffray & Co. (now Piper Sandler & Co.), from September 2011 to August 2013. Ms. Luse has a B.S. in Biochemistry and Mathematics from Indiana University Bloomington. We believe that Ms. Luse is qualified to serve on our board of directors because of her financial expertise, investment experience in the life sciences industry, and service as a director of other biopharmaceutical companies. Ms. Luse has given notice of her intention to resign as a member of our board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.

Aaron Royston, M.D. has served as a member of our board of directors since June 2023. Dr. Royston has been a managing partner at venBio Partners, LLC, a life sciences investment firm, since November 2015. Prior to joining venBio Partners, LLC, Dr. Royston held various positions at Vivo Capital LLC from July 2014 to October 2015, Bain & Company, Inc. from July 2013 to July 2014, and Mount Sinai Medical Center from July 2007 to July 2008. Dr. Royston has served as a member of the board of directors of several publicly traded companies, including RayzeBio, Inc. (acquired by BMS), a biotechnology company, from August 2020 to November 2023, and Ventyx Biosciences, Inc., a biotechnology company, from March 2021 until January 2023. Dr. Royston has a B.S. in Biological Sciences from Duke University, and an M.D. and M.B.A. from the University of Pennsylvania.

James Topper, M.D., Ph.D. has served as Chairman and a member of our board of directors since June 2023. Dr. Topper has served as a Managing Partner of Frazier Life Sciences since 2005 and has been a Partner at Frazier Life Sciences since August 2003. From 2002 to 2003, prior to joining Frazier Life Sciences, Dr. Topper served as head of the Cardiovascular Research and Development Division at Millennium. Dr. Topper currently serves as a member of the board of directors of the following publicly traded companies: Phathom Pharmaceuticals, Inc., a biopharmaceutical company, since September 2022; NewAmsterdam Pharma Company N.V., a biopharmaceutical company, since November 2022. He also served as a member of the board of directors of Alpine Immune Sciences, Inc., a biotechnology company, from June 2016 to May 2024. Dr. Topper received his M.D. and Ph.D. in Biophysics from Stanford University and a B.S. from the University of Michigan. He was board-certified in internal medicine and cardiovascular disease receiving his post-graduate training at the Brigham and Women's Hospital in Boston.

Mr. Josh Ashby has a strong global background in Operations, leading teams in Asia, Europe, Africa and Latin America, and developing operational processes and strategic relationships with large international clients. Prior to joining Atento, he worked as Global Vice President of Operations at Teleperformance, where he spent much of his career in various senior positions, working to transform client operations and build high-performance teams that support strategic initiatives and exceed company goals. Josh holds a Bachelors of science degree in Business Administration from the University of Utah and has several certifications in Lean Six Sigma and DMAIC Methodologies.

Mr. Madden is a Managing Director at HPS Investment Partners. Mr. Madden built his career in global financial institutions in the US and UK. He spent 16 years at Arcapita, a private equity firm, where he worked in both the US and London offices. Mr. Madden holds a BA in Political Economy from Williams College.

From 2013 through March 2016, Mr. Garner served as executive Chairman and a member of the board of directors of BellSystem24. From 2010 through 2013, he served as Chairman and Chief Executive Officer of Sitel Worldwide. From 1998 through 2003, Mr. Garner was President and Chief Executive Officer of SHPS, Inc. Mr. Garner currently serves as a member of the board of directors of National Directory Assistance, LLC. He holds a B.A. in Technical Communications from Louisiana Tech University.

Mr. Rittes is the CEO of Nextel Telecom. Prior to joining Nextel, Mr. Rittes was a principal at H.I.G. Capital, a leading global private equity firm. He also served as COO of Boa Vista Servi c¸os, a Brazilian credit bureau managed by TMG Capital, as CFO of Estre Ambiental, an environmental services group managed by BTG and Angra, and as key officer for Brazilia n telecom companies Brasil Telecom and Oi. Mr. Rittes has an MBA from Harvard Business School and a bachelor's degree s in Business Administration (BBA) with a focus in Public Administration from Funda c¸a~o Getulio Vargas in Sao Paulo, Brazil (FGV).

Mr. Camargo is Co-Founder of Farallon Capital Latin America, part of Farallon Capital Management. Prior to joining Farallon, Antenor was co-founding partner at FKG Capital, a hedge fund focused on Latin America and founded in 2011 in partnership with Farallon and Daniel Goldberg (former CEO of Morgan Stanley in Brazil). Antenor earned his Bachelor's in Business Administration (BBA) with a focus in Business Administration, Management and Finance from Funda c,a~o Getulio Vargas in Sao Paulo, Brazil (FGV)

Bill Payne has over 30 years of executive and management experience in both small, entrepreneurial, and large corporate environments and cultures, having also served in several non-executive, mentoring, advisory and consulting roles. In addition to his current roles at several global start-up companies, such as Room Rocket, Usable Media and Excello, he is a board mentor at Critical Eye, a venture capitalist with UK-based Octopus Investments. He is an experienced Non-Executive Director and Chair as well as a visiting Professor at several business schools, including Lancaster University, Henley Management School, Lyon Business School and the University of Surrey, where he was President of the Surrey Business School MBA program. Earlier in his career, Mr. Payne was a senior executive at IBM, where he held leadership roles in consulting, strategy and process outsourcing in Europe and other geographies, including as General manager of the Global Customer Experience (CRM) Outsourcing Group. Mr. Payne also leads his own strategic consultancy Acadameus, which advises start-ups, mid-caps and high-growth companies

Ms. Kiomara Hidalgo has a global career of over 20 years in Human Resources, developing talent, managing change and strategic planning. Over the years, she has worked professionally in different positions in companies on the Fortune 500 list in international services, health, education, technology and trade sectors. From 2017 to the present, she has held the position of Senior Vice President for Human Resources, Security and Compliance at Grupo Eulen, a general services provider for Spain, Portugal, Chile, Peru, Colombia, and the USA, among others, for the US and Jamaica locations. Prior to that, she spent nearly two years as Global Human Resources, Compliance and Governance Director at Alorica, BPO services company with over 100,000 employees and a presence in 17 countries. At United Data Technologies, a technology solutions integrator that provides services to entities in the public sector and for private businesses in the southeastern and southern regions of the USA, she held the position of Human Resources Vice President (2014 - July 2015) and previously at Bupa Global Market, an international health group, she held the position of Director of Human Resources for Latin America, the Caribbean and the USA and later that of Director of Compliance and Global Employee Relations. She holds a bachelor's degree in Human Resources, a master's degree in Human Resource Sciences from the Florida International University and a variety of international certificates. Certified Senior Professional Human Resources, Society for Human Resources Management, Greater Miami Society for Human Resources Management

Cathrine Jooste, has a successful career spanning over 20 years in the technology and consultancy industries. Prior to joining Atento, she worked as the Microsoft Offering General Manager at DXC Technology. Prior to that post, she worked at Computer Sciences Corporation (CSC), Cognizant Technology Solutions, Systems West Computer Resources, Avanade and Accenture, successfully building and growing her teams within the different global commitments with the clients. Cathrine holds a Bachelor of Science in Business Administration and Information System Management from the University of Florida

Mr. Carlos Lopez-Abadia a long-standing international professional career in the technology, consulting and digital transformation sectors at the global level. His successful professional career spans over thrity years. Prior to his appointment as Atento's Chief Executive Officer, he served as DXC Technology's Vice President and General Manager Consulting, responsible for digital transformation advisory services, including strategic partnerships in the consulting domain. Previously he served as Vice President Global Services for Misys where he led the transformation of the services and software support business and managed a global service delivery network based in major global financial centers and offshore locations. Prior experience also includes, Managing Partner at Accenture and leadership positions at Level 3, McKinsey&Co and AT&T. He holds an MS in electrical engineering from Purdue University and an MBA from Washington University, where he was a Charles F. Knight Scholar. He has recently been named to the Hispanic IT Executive Council's HITEC Top 100, Class of 2017-2018, for his career achievements in information technology

Dimitrius de Oliveira, has more than 20 years' experience in the technology and business services sectors leading sales, after-sales and operations functions formultinational companies such as Atento, Avaya, Ericsson, Nokia, Siemens, Genesys and Contax. Most recently he served as Vice President of Operations for Mutant, former Genesys Prime, a leading provider of digital customer experience solutions in Brazil. Prior to joining Mutant, de Oliveira served as Atento Global Commercial Director and Brazil Multisector Director from 2015 to 2017. Dimitrius de Oliveira has a degree in engineering, with a specialization in building and leading customer centric organizations, from Harvard Business School, as well as an MBA in Marketing from ESPM School of Advertising and Marketing, with a specialization in Leadership from the Sao Paulo Business School and an electrical engineering degree from Universidade de Mogi das Cruzes in Brazi

Mr. Viana-Baptista has had a long-standing and distinguished career in the telecommunications, technology and investment banking sectors as well as in strategic consultancy. He has been over the years an active investor and advisor in technology companies. Most recently, he held the role of Credit Suisse Senior Advisor for Portugal and from 2011 to 2015, Chief Executive Officer for Spain and Portugal. Prior to joining Credit Suisse, he spent over a decade in a number of chief executive roles at Telefonica, including CEO of Telefonica International, Telefonica Spain and Chairman and CEO of Telefonica Moviles among others. Prior to this, he spent seven years at Banco Portugues de Investimento (BPI)as an Executive Board member and was a Partner in the Iberia office of McKinsey & Co. He is currently a Non-Executive Board member at Semapa and Jeronimo Martins. Mr. Viana-Baptista holds a degree in Economics and a Master's in European Economics from Universidad Catolica Portuguesa and an M.B.A. from INSEAD.

Jose Maria Perez Melber, is a renowned professional with over twelve years' general management experience in the services industry and the CRM/BPO sector. He joined Atento in 2014 as Director of EMEA to lead all company activities in the region. Prior to joining Atento, Jose Maria Perez worked as General Director of Operations and was a member of the Management Committee of Orange Spain, leading customer service, customer loyalty and retention, as well as billing and credit management at the company. Jose Maria was previously General Manager for Southern Europe, Latin America and North Africa for Transcom, a BPO/CRM sector company at which he worked for most of his career. Prior to Transcom, Jose Maria led marketing and customer relationships departments in the insurance sector for Mapfre and Hannover International. Jose Maria holds a degree in Business Administration from the Pontifical University of Salamanca.

Virginia Beltramini Trapero has more than thirteen years of experience in management positions in the legal field at, large companies from various sectors. Prior to joining Atento, she held the position of Director of Legal Advice, at Oesia, a multinational consultancy specialized in technology, with a presence in Spain and Latin America, where she was responsible for the legal and corporate governance of the group. Previously, she held management positions at Grupo Lar and Metrovacesa, and worked as a lawyer for 5 years at the firm EY, at its offices in Madrid and New York. She joined Atento in July 2011 and from that date until March 2017 she held the position of Corporate Legal Director. As of March 2017, she was named General Counsel and Secretary of the Board. Virginia has a degree in Law and Legal Practice and a holds a master's degree in Law (LL.M) from IE Business School and an Advanced Programme in Leadership at ESADE Business School

Mr. Jose Antonio de Sousa Azevedo joined Atento with 15 years of experience managing global financial operations from C-suite and Board positions. He has steered major financial turnarounds and corporate mergers at high-profile organizations while implementing financial and business development strategies that drove value forall stakeholders of these companies. Before joining Atento, Mr. Azevedo served as Chief Financial Officer and Investor Relations Officer at Unidas, Brazil's largest fleet management provider and the country's second -largest car rental company. From 2016 to 2017, he served as Country Manager Brazil for Softline Group, a leading global IT solutions and services provider focused on emerging markets. Prior to that role, Mr. Azevedo was Chief Executive Officer at Globalweb Data Services in 2015 and Chief Financial Officer at this company from 2014 to 2015. He also served as Chief Financial Officer of Estre Ambiental from 2013 to 2014 and held several leadership positions at Latam Airlines from 2008 to 2013.Mr. Azevedo holds an MBA from Hamburg University, a BBA from the Automous University of Lisbon, and has CBA training in finance and management from Harvard University